glp 1 parkinson's Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment GLP-1 Receptor Agonists: A New

Although several psychological factors (for example, deficit in impulse control) are known to play a major role in the pathophysiology of obesity 248 , we here raise the issue of disparity in the provision of psychiatric care for the treatment of obesity compared with other eating disorders, which are predominantly treated by psychiatrists, and advocate for the importance of a multidisciplinary, integrated approach to weight management

Comparing Patchie GLP-1 Patches vs Alternatives in 2025 The health and wellness market in 2025 features an expanding range of products inspired by the GLP-1 trend

Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with CVD and either obesity or overweight, John Sharretts, MD, director of the division of diabetes, lipid disorders and obesity in the FDAs Center for Drug Evaluation and Research, said in the statement

Together, these observations suggest that receptor-level signaling and anti-inflammatory effects alone may be insufficient to produce functional improvement in energy-demanding tissues such as skeletal muscle and brain, where substrate turnover and mitochondrial metabolic throughput are critical determinants of tissue function

Phentermine alone is designed for short-term use only, as there are few long-term studies on its safety

Mental disorder comorbidity and treatment utilization